Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
06. August 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral...
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
02. Mai 2024 07:00 ET
|
Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
18. September 2023 09:05 ET
|
Atriva Therapeutics GmbH
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the...
Sirona Biochem Corporate Update
13. Juli 2023 09:00 ET
|
Sirona Biochem Corp.
VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased...
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
28. Juni 2023 09:00 ET
|
Sirona Biochem Corp.
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is excited to announce the development of a...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
07. Juni 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
23. Mai 2023 16:05 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
04. Mai 2023 06:45 ET
|
NanoViricides, Inc.
SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage global leader in the development of highly effective...
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
18. April 2023 08:00 ET
|
Assembly Biosciences, Inc.
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and...
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
29. März 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral...